Defining the Mechanism of Action and Enzymatic Selectivity of Psammaplin A against Its Epigenetic Targets
The DOI matches its Crossref record; 80 of the 81 references it cites were found in a registry or an index.
Abstract
Psammaplin A (11c) is a marine metabolite previously reported to be a potent inhibitor of two classes of epigenetic enzymes: histone deacetylases and DNA methyltransferases. The design and synthesis of a focused library based on the psammaplin A core has been carried out to probe the molecular features of this molecule responsible for its activity. By direct in vitro assay of the free thiol generated upon reduction of the dimeric psammaplin scaffold, we have unambiguously demonstrated that 11c functions as a natural prodrug, with the reduced form being highly potent against HDAC1 in vitro (IC(50) 0.9 nM). Furthermore, we have shown it to have high isoform selectivity, being 360-fold selective for HDAC1 over HDAC6 and more than 1000-fold less potent against HDAC7 and HDAC8. SAR around our focused library revealed a number of features, most notably the oxime functionality to be important to this selectivity. Many of the compounds show significant cytotoxicity in A549, MCF7, and W138 cells, with the SAR of cytotoxicity correlating to HDAC inhibition. Furthermore, compound treatment causes upregulation of histone acetylation but little effect on tubulin acetylation. Finally, we have found no evidence for 11c functioning as a DNMT inhibitor.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, romidepsin and psammaplin A (Figure 15A) contain disulfide bridges that are reduced in the intracellular environment to generate free thiols that are capable of Zn2+-chelation (Figure 15B) [84, 85].”
From Medicinal chemistry advances in targeting class I histone deacetylases (2023) · cites this paper as [84]
Citations
Cites
GROMACS 4: Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular Simulation
Hess, B., Kutzner, C., van der Spoel, D., & Lindahl, E. (2008) · Journal of Chemical Theory and Computation · doi:10.1021/ct700301q · Cited by 15,908
Spectrometric Identification of Organic Compounds
Silverstein, R. M., & Bassler, G. C. (1962) · Journal of Chemical Education · doi:10.1021/ed039p546 · Cited by 14,272
New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening
Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., & Boyd, M. R. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.13.1107 · Cited by 9,766
The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling
Arnold, K., Bordoli, L., Kopp, J., & Schwede, T. (2006) · Bioinformatics · doi:10.1093/bioinformatics/bti770 · Cited by 6,988
Automatic atom type and bond type perception in molecular mechanical calculations
Wang, J., Wang, W., Kollman, P. A., & Case, D. A. (2006) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2005.12.005 · Cited by 5,477
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., & Pavletich, N. P. (1999) · Nature · doi:10.1038/43710 · Cited by 1,714
DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA
Ooi, S. K. T., Qiu, C., Bernstein, E., Li, K., Jia, D., Yang, Z., Erdjument-Bromage, H., Tempst, P., Lin, S.-P., Allis, C. D., et al. (2007) · Nature · doi:10.1038/nature05987 · Cited by 1,567
Histone deacetylase inhibitors: molecular mechanisms of action
Xu, W. S., Parmigiani, R. B., & Marks, P. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210620 · Cited by 1,542
Histone-deacetylase inhibitors: novel drugs for the treatment of cancer
Johnstone, R. W. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd772 · Cited by 1,515
Dnmt3L and the Establishment of Maternal Genomic Imprints
Bourc'his, D., Xu, G.-L., Lin, C.-S., Bollman, B., & Bestor, T. H. (2001) · Science · doi:10.1126/science.1065848 · Cited by 1,439
Research works printed but not linked: 4
- Fang M. Z., 2003, Cancer Res., 63, 7563
- Kim D., 1999, Anticancer Res., 19, 4085
- Furumai R., 2002, Cancer Res., 62, 4916
- Zhu Y., 2009, Mol. Med. Rep., 2, 743
Cited by
DNA methylation inhibitors in cancer: Recent and future approaches
Gros, C., Fahy, J., Halby, L., Dufau, I., Erdmann, A., Gregoire, J.-M., Ausseil, F., Vispé, S., & Arimondo, P. B. (2012) · Biochimie · doi:10.1016/j.biochi.2012.07.025 · Cited by 245
“Nevertheless, no DNA demethylation has been highlighted in HCT116 cells [195], and, in a recent study, psammaplin A exhibited no activity on DNMT1 at 30 and 120 mM [196], in agreement with the study of Lera et al.”
ResultTrials with ‘epigenetic’ drugs: An update
Nebbioso, A., Carafa, V., Benedetti, R., & Altucci, L. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.09.004 · Cited by 237
“…tumor cell growth in a A549 lung xenograft mouse model, DNMT inhibi- tion was not followed by DNA demethylation and re- expression of tumor suppressor genes, suggesting that an in- tracellular target different from DNMT1 is responsible for the cytotoxic effect of the molecule (Baud et al., 2012).”
BackgroundDiscovery of bioactive molecules from CuAAC click-chemistry-based combinatorial libraries
Wang, X., Huang, B., Liu, X., & Zhan, P. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2015.08.004 · Cited by 190
Recent progress in DNA methyltransferase inhibitors as anticancer agents
Zhang, Z., Wang, G., Li, Y., Lei, D., Xiang, J., Ouyang, L., Wang, Y., & Yang, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1072651 · Cited by 162
“, 2011), and it was further confirmed that histone deacetylases are the main target of Psammaplin and not DNMT (Baud et al., 2012).”
BackgroundFahy, J., Jeltsch, A., & Arimondo, P. B. (2012) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2012.729579 · Cited by 115
“Most recently, it was further confirmed that histone deacetylases are the main target of psammaplin and not DNMT [75].”
Background
Metadata
- Authors
- Baud, M. G. J., Leiser, T., Haus, P., Samlal, S., Wong, A. C., Wood, R. J., Petrucci, V., Gunaratnam, M., Hughes, S. M., Buluwela, L., Turlais, F., Neidle, S., Meyer-Almes, F.-J., White, A. J. P., & Fuchter, M. J.
- Affiliations
- Imperial College London (GB)
- Darmstadt University of Applied Sciences (DE)
- Cancer Research Technology Discovery Laboratories, Wolfson Institute for Biomedical Research, The Cruciform Building, Gower Street, London WC1E 6BT, United Kingdom
- Cancer Research UK (GB)
- Department of Surgery and Cancer, Imperial College London, Du Cane Road, London W12 0NN, United Kingdom
- Department of Chemical Engineering and Biotechnology, University of Applied Sciences, Schnittspahnstrasse 12, 64287 Darmstadt, Germany
- Corresponding author
- Fuchter, Matthew J.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2012-02-09
- Volume
- 55
- Issue
- 4
- Pages
- 1731-1750
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2064944074
- Cited by
- 100
- References
- 81
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 5 · 2023: 7 · 2022: 6 · 2021: 10 · 2020: 5 · 2019: 7 · 2018: 8 · 2017: 7 · 2016: 8 · 2015: 12 · 2014: 7 · 2013: 6 · 2012: 7
- FWCI
- 4.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Physical Sciences › Chemistry › Organic Chemistry › Isoquinoline Alkaloid Synthesis
- Keywords
- psammaplin A, histone deacetylase inhibitors, HDAC1, HDAC isoform selectivity, structure-activity relationship, marine natural products, cytotoxicity, histone acetylation, DNA methyltransferase inhibition, focused libraries
- MeSH terms
- Acetylation, Antineoplastic Agents, Disulfides, DNA (Cytosine-5-)-Methyltransferases, Drug Screening Assays, Antitumor, Histones, Humans, Isoenzymes, Models, Molecular, Prodrugs, Structure-Activity Relationship, Tubulin, Tyrosine, Crystallography, X-Ray, Dimerization, Epigenesis, Genetic, Cell Line, Tumor, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.